Joyzyme Group 8622.HK · HKD

Its shares trade on HKEX under the ticker 8622.HK. It has been listed since 13 December 2018. In the fiscal year to 31 December 2025, it reported revenue of CN¥28.3m and a net loss of CN¥5.0m. At that date it held total assets of CN¥66.6m and shareholders' equity of CN¥51.2m.

Huakang Biomedical Holdings Co. Ltd. operates as a medical group company. The company employs 73 full-time employees The company went IPO on 2018-12-13. The IVD reagents include male fertility IVD reagents, Epstein-Barr virus antibody detection reagents ad parasite antibody detection reagents, among others. The male fertility IVD reagents include sperm function test products, accessory genital glands test products, anti-sperm antibody test products, as well as male reproductive tract infection test products, among others. In addition, the Company is also involved in the sale of auxiliary reproductive supplies and equipments, such as glass coverslips and sperm sample collection cups.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Shuguang ZhangExecutive Chairman of the Board, since 2017CN¥333,000
• Mr. Chunguang ZhangChief Executive Officer, Executive Director, since 2017CN¥399,000
• Mr. Lai Yin PoonChief Financial Officer, Compliance Officer, Executive Director, since 2017CN¥1.0m
• Mr. Yim Yang ChangVice Chairman of the Board, Director of Shenzhen Huakang Bio-Medical Engineering Limited
• Mr. Jianhua FuChief Technology Officer, Deputy General Manager of Shenzhen Huakang
• Mr. Jiaming HeExecutive DirectorCN¥445,000
• Mr. Lai Ki ChauCompany Secretary, Financial Controller
• Dr. Su BuNon-Executive Director
• Dr. Ming XuNon-Executive Director
• Dr. Faat Ting ChengIndependent Non-Executive DirectorCN¥83,000
• Dr. Kwok Fai ChowIndependent Non-Executive DirectorCN¥83,000
• Mr. Wing Tak TsuiIndependent Non-Executive Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.